Birdwatch Note
2024-05-01 01:14:25 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
EBC-46 is a compound with potential anti-cancer properties that has been successfully used in veterinary medicine and is currently being studied for use in humans. However, the claim of it killing cancer in 48 hours should be viewed in the context of ongoing research. https://news.stanford.edu/2022/10/03/breakthrough-production-acclaimed-cancer-treating-drug/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268252/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182759/ https://www.europeanpharmaceuticalreview.com/news/175005/novel-cancer-therapeutic-synthesised-by-stanford-researchers/
Written by 8E0782E7F593AE43DE132F9A686B9623FE5078AF96C0655960B8BBFA4E740320
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1785425279940469212
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1785477845596467593
- noteId - 1785477845596467593
- participantId -
- noteAuthorParticipantId - 8E0782E7F593AE43DE132F9A686B9623FE5078AF96C0655960B8BBFA4E740320 Participant Details
- createdAtMillis - 1714526065623
- tweetId - 1785425279940469212
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- EBC-46 is a compound with potential anti-cancer properties that has been successfully used in veterinary medicine and is currently being studied for use in humans. However, the claim of it killing cancer in 48 hours should be viewed in the context of ongoing research. https://news.stanford.edu/2022/10/03/breakthrough-production-acclaimed-cancer-treating-drug/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268252/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182759/ https://www.europeanpharmaceuticalreview.com/news/175005/novel-cancer-therapeutic-synthesised-by-stanford-researchers/
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2024-05-01 01:14:25 UTC (1714526065623) |
2024-05-01 09:38:18 UTC (1714556298819) |
CURRENTLY_RATED_HELPFUL | 2024-05-01 12:35:12 UTC (1714566912495) |
CURRENTLY_RATED_HELPFUL | 2024-05-01 09:38:18 UTC (1714556298819) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
| rated at | rated by | |
| 2024-05-01 10:05:01 -0500 | Rating Details | |
| 2024-05-01 06:47:18 -0500 | Rating Details | |
| 2024-05-01 06:41:28 -0500 | Rating Details | |
| 2024-05-01 02:37:56 -0500 | Rating Details | |
| 2024-05-01 01:48:01 -0500 | Rating Details | |
| 2024-04-30 22:19:29 -0500 | Rating Details | |
| 2024-04-30 22:09:13 -0500 | Rating Details | |
| 2024-04-30 22:03:36 -0500 | Rating Details | |
| 2024-04-30 21:45:38 -0500 | Rating Details | |
| 2024-04-30 21:30:34 -0500 | Rating Details | |
| 2024-04-30 21:29:53 -0500 | Rating Details | |
| 2024-04-30 21:09:54 -0500 | Rating Details | |
| 2024-04-30 20:59:07 -0500 | Rating Details | |
| 2024-04-30 20:33:13 -0500 | Rating Details | |
| 2024-04-30 20:31:39 -0500 | Rating Details | |
| 2024-04-30 20:30:18 -0500 | Rating Details | |
| 2024-04-30 20:27:58 -0500 | Rating Details | |
| 2024-04-30 20:22:23 -0500 | Rating Details | |
| 2024-04-30 20:21:47 -0500 | Rating Details | |
| 2024-05-01 10:56:31 -0500 | Rating Details | |
| 2024-05-01 07:09:52 -0500 | Rating Details | |
| 2024-05-01 06:14:43 -0500 | Rating Details | |
| 2024-05-01 05:40:27 -0500 | Rating Details | |
| 2024-05-01 04:48:27 -0500 | Rating Details | |
| 2024-05-01 03:21:41 -0500 | Rating Details | |
| 2024-05-01 02:00:18 -0500 | Rating Details | |
| 2024-05-01 01:31:35 -0500 | Rating Details | |
| 2024-05-01 01:07:59 -0500 | Rating Details | |
| 2024-05-01 01:04:55 -0500 | Rating Details | |
| 2024-05-01 00:05:00 -0500 | Rating Details | |
| 2024-04-30 23:37:44 -0500 | Rating Details | |
| 2024-04-30 23:05:59 -0500 | Rating Details | |
| 2024-04-30 22:32:29 -0500 | Rating Details | |
| 2024-04-30 22:18:21 -0500 | Rating Details | |
| 2024-04-30 21:51:39 -0500 | Rating Details | |
| 2024-04-30 21:46:53 -0500 | Rating Details | |
| 2024-04-30 21:38:50 -0500 | Rating Details | |
| 2024-04-30 21:24:57 -0500 | Rating Details | |
| 2024-04-30 20:42:07 -0500 | Rating Details | |
| 2024-04-30 20:39:13 -0500 | Rating Details | |
| 2024-04-30 20:34:18 -0500 | Rating Details | |
| 2024-04-30 20:26:27 -0500 | Rating Details | |
| 2024-04-30 20:23:26 -0500 | Rating Details | |
| 2024-04-30 20:17:25 -0500 | Rating Details | |
| 2024-04-30 20:17:08 -0500 | Rating Details | |
| 2024-05-03 11:15:38 -0500 | Rating Details | |
| 2024-05-02 01:38:27 -0500 | Rating Details | |
| 2024-05-01 09:26:05 -0500 | Rating Details | |
| 2024-05-01 07:55:34 -0500 | Rating Details | |
| 2024-05-01 04:45:15 -0500 | Rating Details | |
| 2024-05-01 02:41:07 -0500 | Rating Details | |
| 2024-05-01 00:18:33 -0500 | Rating Details | |
| 2024-04-30 21:50:59 -0500 | Rating Details | |
| 2024-04-30 21:42:27 -0500 | Rating Details | |
| 2024-04-30 21:38:51 -0500 | Rating Details | |
| 2024-04-30 21:34:17 -0500 | Rating Details | |
| 2024-04-30 21:32:36 -0500 | Rating Details | |
| 2024-04-30 21:04:39 -0500 | Rating Details | |
| 2024-04-30 20:54:18 -0500 | Rating Details | |
| 2024-04-30 20:19:52 -0500 | Rating Details | |
| 2024-04-30 20:18:54 -0500 | Rating Details | |
| 2024-04-30 20:18:34 -0500 | Rating Details | |
| 2024-05-03 09:38:36 -0500 | Rating Details | |
| 2024-05-02 14:47:34 -0500 | Rating Details | |
| 2024-05-02 14:39:58 -0500 | Rating Details | |
| 2024-05-03 12:04:32 -0500 | Rating Details | |
| 2024-05-01 14:46:13 -0500 | Rating Details | |
| 2024-05-01 04:04:39 -0500 | Rating Details | |
| 2024-05-01 02:14:18 -0500 | Rating Details | |
| 2024-05-01 01:45:04 -0500 | Rating Details | |
| 2024-05-01 01:36:54 -0500 | Rating Details | |
| 2024-05-01 01:26:22 -0500 | Rating Details | |
| 2024-04-30 23:44:20 -0500 | Rating Details | |
| 2024-04-30 23:16:32 -0500 | Rating Details | |
| 2024-04-30 23:04:40 -0500 | Rating Details | |
| 2024-04-30 22:23:53 -0500 | Rating Details | |
| 2024-04-30 21:24:55 -0500 | Rating Details | |
| 2024-04-30 21:04:26 -0500 | Rating Details | |
| 2024-04-30 21:03:29 -0500 | Rating Details | |
| 2024-04-30 21:01:10 -0500 | Rating Details | |
| 2024-04-30 20:49:46 -0500 | Rating Details | |
| 2024-04-30 20:45:10 -0500 | Rating Details | |
| 2024-04-30 20:43:50 -0500 | Rating Details | |
| 2024-04-30 20:32:08 -0500 | Rating Details | |
| 2024-04-30 20:20:03 -0500 | Rating Details | |
| 2024-05-01 06:39:19 -0500 | Rating Details | |
| 2024-04-30 20:27:15 -0500 | Rating Details | |
| 2024-05-03 05:40:31 -0500 | Rating Details | |
| 2024-05-01 08:37:54 -0500 | Rating Details | |
| 2024-05-01 07:01:22 -0500 | Rating Details |